BackOpus Genetics Overview

Opus Genetics EBIT

Track Opus Genetics's EBIT ($-71M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$46.50M
↓ 167.43% YoY

As of Sep 30, 2026

Annual EBIT (TTM)

-$70.83M
↑ 4.39% YoY

Trailing 12 months ending Sep 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Opus Genetics (IRD) FAQ

The latest EBIT for IRD is $-71M as of September 2026. That compares with $-74M in the prior-year period — up 4.4% year over year. That is below the Healthcare sector average of $1.9T. Investors often review this figure alongside Opus Genetics's historical trend and sector peers before judging valuation or financial health.

Over the past year, IRD's EBIT moved from $-74M to $-71M — a 4.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Opus Genetics's operating scale or balance-sheet position.

Against Healthcare companies, IRD currently prints $-71M for EBIT, while the sector average sits near $1.9T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Opus Genetics's growth, margins, and balance sheet.

A EBIT figure of $-71M for IRD is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.9T. Explore the charts below for those layers of context.

After noting IRD's EBIT ($-71M), review year-over-year change from $-74M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.